Elisa Agostinetto: Commentary on the updated results of DestinyBreast03
Elisa Agostinetto shared on X/Twitter:
“Out commentary on the updated results of DestinyBreast03 is out on PracticeUpdate, Elsevier.
T-DXd increased PFS of 4 times compared to T-DM1 and increased OS of ~10months.
These results confirm its role as standard of care in 2 line.”
Source: Elisa Agostinetto/X
Dr. Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Trained in Milan, Italy, she currently conducts advanced research at Institut Jules Bordet – Université Libre de Bruxelles in Brussels, Belgium.
Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023